Claim Your New User Special: Get your second month free ▶ Second Month Free

Serving leading biopharmaceutical companies globally:

Moodys
Boehringer Ingelheim
Dow
Express Scripts
McKesson
Medtronic

Last Updated: June 29, 2022

Investigational Drug Information for Namilumab


✉ Email this page to a colleague

« Back to Dashboard

What is the drug development status for Namilumab?

Namilumab is an investigational drug.

There have been 7 clinical trials for Namilumab. The most recent clinical trial was a Phase 2 trial, which was initiated on June 1st 2014.

The most common disease conditions in clinical trials are Arthritis, Rheumatoid, Arthritis, and Sarcoidosis. The leading clinical trial sponsors are Takeda, Kinevant Sciences GmbH, and [disabled in preview].

There are two US patents protecting this investigational drug and twelve international patents.

Recent Clinical Trials for Namilumab
TitleSponsorPhase
A Study to Assess the Efficacy and Safety of Namilumab in Participants With Chronic Pulmonary SarcoidosisKinevant Sciences GmbHPhase 2
A Study to Assess the Safety, Tolerability, and Efficacy of Namilumab in Participants With Active Cardiac SarcoidosisKinevant Sciences GmbHPhase 2
Namilumab vs Adalimumab in Participants With Moderate to Severe Early Rheumatoid Arthritis Inadequately Responding to MethotrexateTakedaPhase 2

See all Namilumab clinical trials

Clinical Trial Summary for Namilumab

Top disease conditions for Namilumab
Top clinical trial sponsors for Namilumab

See all Namilumab clinical trials

US Patents for Namilumab

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Namilumab See Plans and Pricing Cholestosome vesicles for incorporation of molecules into chylomicrons THERASYN SENSORS, INC. (Eggertsville, NY) See Plans and Pricing
Namilumab See Plans and Pricing Binding-triggered transcriptional switches and methods of use thereof The Regents of the University of California (Oakland, CA) See Plans and Pricing
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Namilumab

Drugname Country Document Number Estimated Expiration Related US Patent
Namilumab Australia AU2014236559 2033-03-14 See Plans and Pricing
Namilumab Brazil BR112015022936 2033-03-14 See Plans and Pricing
Namilumab Canada CA2905108 2033-03-14 See Plans and Pricing
Namilumab China CN105164143 2033-03-14 See Plans and Pricing
Namilumab European Patent Office EP2970369 2033-03-14 See Plans and Pricing
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Boehringer Ingelheim
Dow
Express Scripts
McKesson
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.